LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa?) in Lumbosacral Radicular Pain CI
Sector Update: Health Care Stocks Rise Premarket Wednesday MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of US FOMC Announcement MT
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Scilex Shares Advance after FDA Approves Production of Gout Medication MT
Scilex Holding Company Announces FDA Approval of Commercial Manufacturing of Gloperba CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Scilex Asks SEC, FINRA to Probe Alleged Market Manipulation in Stock MT
Sector Update: Health Care Stocks Decline Late Friday Afternoon MT
Sector Update: Health Care MT
Scilex to Join MSCI Global Small Cap Index MT
Scilex Calls for Investigation Into Alleged 'Naked Short' Stock Manipulation MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Holding Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Scilex Issues Preliminary Q1 Sales Results for ZTlido MT
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label MT
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba MT
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed CI
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Decliners MT
Chart Scilex Holding Company
More charts
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.785 USD
Average target price
5.333 USD
Spread / Average Target
+198.79%
Consensus
  1. Stock Market
  2. Equities
  3. SCLX Stock
  4. News Scilex Holding Company
  5. Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs